<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34993972</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1099-0801</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomedical chromatography : BMC</Title>
          <ISOAbbreviation>Biomed Chromatogr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development and validation of liquid chromatography-tandem mass spectrometry method for the estimation of a potential genotoxic impurity 2-(2-chloroethoxy)ethanol in hydroxyzine.</ArticleTitle>
        <Pagination>
          <StartPage>e5325</StartPage>
          <MedlinePgn>e5325</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/bmc.5325</ELocationID>
        <Abstract>
          <AbstractText>2-(2-Chloroethoxy)ethanol (CEE) belongs to the so-called cohort of concerns which were classified as highly potent mutagenic carcinogens by the World Health Organization. It is widely used in the synthesis of the essential anti-histamine drug hydroxyzine. In addition, it is used as a primary solvent in dyes, nitrocellulose, paints, inks and resins. Owing to its potential genotoxicity, an efficient liquid chromatography-tandem mass spectrometry method was developed for the quantitative estimation of CEE traces in an active pharmaceutical ingredients and in tablet dosage forms of hydroxyzine-free base. The chromatographic separation was achieved on a C<sub>18</sub> column using a gradient elution mode with a binary solvent system (ammonium formate and methanol). Mass detection was performed for CEE using a positive mode with selected ion monitoring technique at m/z value of [M + NH<sub>4</sub> ]<sup>+</sup> . The developed method was validated as per the International Conference on Harmonizaiton guidelines. The quantitation limit, linearity and recoveries were found to be 0.56 ppm, 0.56-7.49 ppm (r<sup>2</sup>  &gt; 0.9985) and 93.6-99.3%, respectively. The proposed method was highly compatible and was used effectively to estimate CEE traces in different stages of drug synthesis and in tablet dosage forms of hydroxyzine for routine and stability testing.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lakka</LastName>
            <ForeName>Narasimha S</ForeName>
            <Initials>NS</Initials>
            <Identifier Source="ORCID">0000-0002-2952-7493</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Chemistry, Department of Sciences and Humanities, VIGNAN's Foundation for Science, Technology &amp; Research, Vadlamudi, Guntur (Dist.), India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuppan</LastName>
            <ForeName>Chandrasekar</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-3780-6222</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Chemistry, Department of Sciences and Humanities, VIGNAN's Foundation for Science, Technology &amp; Research, Vadlamudi, Guntur (Dist.), India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ravinathan</LastName>
            <ForeName>Poornima</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Sciences and Humanities, JMJ College for Women, Tenali, Guntur (Dist.), India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palakurthi</LastName>
            <ForeName>Ashok Kumar</ForeName>
            <Initials>AK</Initials>
            <Identifier Source="ORCID">0000-0001-5658-8622</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Analytical Research and Development, Aurex Laboratories LLC, East Windsor, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>WHO_</Acronym>
            <Agency>World Health Organization</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biomed Chromatogr</MedlineTA>
        <NlmUniqueID>8610241</NlmUniqueID>
        <ISSNLinking>0269-3879</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005019">Ethyl Ethers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012997">Solvents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3K9958V90M</RegistryNumber>
          <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R2UP818L4I</RegistryNumber>
          <NameOfSubstance UI="C523281">2-(2-chloroethoxy)ethanol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005019" MajorTopicYN="N">Ethyl Ethers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="Y">Hydroxyzine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053719" MajorTopicYN="Y">Tandem Mass Spectrometry</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2-(2-chloroethoxy)ethanol (CEE)</Keyword>
        <Keyword MajorTopicYN="N">atmospheric pressure chemical ionization (APCI)</Keyword>
        <Keyword MajorTopicYN="N">hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">liquid chromatography-tandem mass spectrometry (LC-MS/MS)</Keyword>
        <Keyword MajorTopicYN="N">potential genotoxic impurity (PGI)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>48</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34993972</ArticleId>
        <ArticleId IdType="doi">10.1002/bmc.5325</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Agilent. (2007). Familiarization guide. Agilent MassHunter workstation software data acquisition for 6200 series TOF and 6500 series Q-TOF (2006-2007. 1st ed.) (pp. G3335-G90029). Agilent Technologies, Inc.</Citation>
        </Reference>
        <Reference>
          <Citation>Agilent. (2010). Familiarization guide. Agilent MassHunter workstation software quantitative analysis. Agilent Technologies, Inc. (2007-2010, 4th edn) (pp. G3335-G90061). Agilent Technologies, Inc. https://www.agilent.com/cs/library/usermanuals/Public/G3335_90061_Quant_Familiarization-EN.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Alquadeib, B. T. (2019). Development and validation of a new HPLC analytical method for the determination of diclofenac in tablets. Saudi Pharmaceutical Journal., 27, 66-70. https://doi.org/10.1016/j.jsps.2018.07.020</Citation>
        </Reference>
        <Reference>
          <Citation>Colby, J. M., &amp; Thoren, K. L. (2020). Applications of mass spectrometry in the clinical laboratory. In Contemporary Practice in Clinical Chemistry (Fourth ed.) (pp. 351-363). Academic Press. https://doi.org/10.1016/B978-0-12-815499-1.00021-1</Citation>
        </Reference>
        <Reference>
          <Citation>Ellis-Davies, G. C., &amp; Kaplan, J. H. (1994). Nitrophenyl-EGTA, a photolabile chelator that selectively binds Ca2+ with high affinity and releases it rapidly upon photolysis. Proceedings of the National Academy of Sciences of the United States of America, 91(1), 187-191. https://doi.org/10.1073/pnas.91.1.187</Citation>
        </Reference>
        <Reference>
          <Citation>EMEA. (2006). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02 EMEA/CHMP/QWP/251344/2006. European Medicines Agency Evaluation of Medicines for Human Use. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-limits-genotoxic-impurities_en.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>EMEA. (2010). Safety working group, questions and answers on the ‘Guideline on the limits of genotoxic impurities’. 23 September 2010. EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP). Academic Press. https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-guideline-limits-genotoxic-impurities_en.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. (2008). FDA draft guidance, genotoxic and carcinogenic impurities in drug substances and products: Recommended approaches (242th ed., Vol. 73, pp. 76361-76362). USA: U.S FDA. https://www.govinfo.gov/content/pkg/FR-2008-12-16/pdf/E8-29674.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. (2018). M7(R1): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, guidance for industry. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). https://www.fda.gov/media/85885/download</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. (2021). Hydroxyzine hydrochloride, accessed on July 25, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/088617Orig1s043,088618Orig1s043,088619Orig1s044lbl.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Gosar, A., Sayyed, H., &amp; Shaikh, T. (2018). Genotoxic impurities and its risk assessment in drug compounds. Drug Designing &amp; Intellectual Properties International, 2(4), 227-232. https://doi.org/10.32474/DDIPIJ.2018.02.000143</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (1996). Stability testing: Photostability testing of new drug substances and products, Q1B, current step 4 version, dated 6 November 1996. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (2003). Stability testing of new drug substances and products Q1A (R2), current step 4 version, dated 6 February 2003. ICH. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (2021a). Impurities: Guideline for residual solvents Q3C(R8), current step 4 version, dated 22 April 2021. ICH. https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (2021b). M7(R1) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, accessed on 20 July, 2021. ICH. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (2005). Q2(R1) Validation of analytical procedures: Definitions and methodology. Incorporated in Q2(R1)</Citation>
        </Reference>
        <Reference>
          <Citation>ICH. (2011). S2(R1) Genotoxicity testing and data interpretation for pharmaceuticals intended for human use.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirkland, D., &amp; Snodin, D. (2004). Setting limits for genotoxic impurities in drug substances, threshold-based and pragmatic approaches. International Journal of Pharmaceutical Medicine, 18, 197-207. https://doi.org/10.1097/00124363-200418040-00001</Citation>
        </Reference>
        <Reference>
          <Citation>Lakka, N. S., Kuppan, C., &amp; Ravinathan, P. (2021). Impurity profiling and stability-indicating method development and validation for the estimation of assay and degradation impurities of midostaurin in softgel capsules using HPLC and LC-MS. Biomedical Chromatography, e5222, e5222. https://doi.org/10.1002/bmc.5222</Citation>
        </Reference>
        <Reference>
          <Citation>Lee, H.-R., Kochhar, S., &amp; Shim, S.-M. (2015). Comparison of electrospray ionization and atmospheric chemical ionization coupled with the liquid chromatography-tandem mass spectrometry for the analysis of cholesteryl esters. International Journal of Analytical Chemistry, 2015, 1-6. https://doi.org/10.1155/2015/650927</Citation>
        </Reference>
        <Reference>
          <Citation>McClay, K., Schaefer, C. E., Vainberg, S., &amp; Steffan, R. J. (2007). Biodegradation of Bis(2-chloroethyl) ether by Xanthobacter sp. strain ENV481. Applied and Environmental Microbiology, 73, 6870-6875. https://doi.org/10.1128/AEM.01379-07</Citation>
        </Reference>
        <Reference>
          <Citation>Mespouille, L., Vachaudez, M., Suriano, F., Gerbaux, P., Coulembier, O., Degée, P., Flammang, R., &amp; Dubois, P. (2007). One-pot synthesis of well-defined amphiphilic and adaptative block copolymers via versatile combination of “click” chemistry and ATRP. Macro Molecular Rapid Communications, 28(22), 2151-2215. https://doi.org/10.1002/marc.200700400</Citation>
        </Reference>
        <Reference>
          <Citation>Miller, J. N. (1991). Basic statistical methods for analytical chemistry. Part 2. Calibration and regression methods. A review. The Analyst, 116, 3-14. https://doi.org/10.1039/AN9911600003</Citation>
        </Reference>
        <Reference>
          <Citation>Müller, L., Mauthe, R. J., Riley, C. M., Andino, M. M., De Antonis, D., Beels, C., DeGeorge, J., De Knaep, A. G. M., Ellison, D., Fagerland, J. A., Frank, R., Fritschel, B., Galloway, S., Harpur, E., Humfrey, C. D. N., Jacks, A. S., Jagota, N., Mackinnon, J., Mohan, G., … Yotti, L. (2006). A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regulatory Toxicology and Pharmacology, 44(3), 198-211. https://doi.org/10.1016/j.yrtph.2005.12.001</Citation>
        </Reference>
        <Reference>
          <Citation>Narasimha, S. L., &amp; Chandrasekar, K. (2019). Principles of chromatography method development. In O.-M. Boldura, C. Balta, &amp; N. S. Awwad (Eds.), Biochemical analysis tools-Methods for bio-molecules studies. IntechOpen. https://doi.org/10.5772/intechopen.89501</Citation>
        </Reference>
        <Reference>
          <Citation>Narasimha, S. L., Chandrasekar, K., Kona, S. S., &amp; Raviteja, Y. (2020). Separation and characterization of new forced degradation products of Dasatinib in tablet dosage formulation using LC-MS and stability-indicating HPLC methods. Chromatographia, 83, 947-962. https://doi.org/10.1007/s10337-0</Citation>
        </Reference>
        <Reference>
          <Citation>Petras, D., Koester, I., Da Silva, R., Stephens, B. M., Haas, A. F., Nelson, C. E., Kelly, L. W., Aluwihare, L. I., &amp; Dorrestein, P. C. (2017). High-resolution liquid chromatography tandem mass spectrometry enables large scale molecular characterization of dissolved organic matter. Frontiers in Marine Science, 4(405). 1-14. https://doi.org/10.3389/fmars.2017.00405</Citation>
        </Reference>
        <Reference>
          <Citation>Pitt, J. J. (2009). Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clinical Biochemist Reviews, 30, 19-34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643089/pdf/CBR_30_19.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Stolarczyk, E. U., Groman, A., &amp; Maruszak, W. (2011). Validation of GC method for quantitative determination of residual 2-(2-chloroethoxy)ethanol (CEE) and N-methyl-2-pyrrolidinone (NMP) in pharmaceutical active substance. Acta Poloniae Pharmaceutica. Drug Research, 68(2), 161-167.</Citation>
        </Reference>
        <Reference>
          <Citation>Stolarczyk, E. U., Groman, A., Groman, A., Kaczmarek, L. S., &amp; Gołebiewski, P. (2007). GC method for quantitative determination of residual 2-(2-chloroethoxy) ethanol (CEE) and N-methyl-2-pyrrolidinone (NMP) in quetiapine. Acta Poloniae Pharmaceutica, 64(2), 187-189.</Citation>
        </Reference>
        <Reference>
          <Citation>Thomas, S. N. (2019). Mass spectrometry. In Contemporary Practice in Clinical Chemistry (4th ed.) (pp. 171-185). Academic Press. https://doi.org/10.1016/B978-0-12-815499-1.00010-7</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson, M., Ellison, S. L. R., &amp; Wood, R. (2002). Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC technical report). Pure and Applied Chemistry, 74(5), 835-855. https://doi.org/10.1351/pac200274050835</Citation>
        </Reference>
        <Reference>
          <Citation>Vogelgesang, J., &amp; Hädrich, J. (1998). Limits of detection, identification and determination: A statistical approach for practitioners. Accreditation and Quality Assurance, 3, 242-255. https://doi.org/10.1007/s007690050234</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
